• Citer

A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923.

par Hamilton, Andrew;Larsimont, Denis ;Paridaens, R. ;Drijkoningen, M;Van de Vijver, Marc J;Bruning, Peter;Hanby, A;Houston, S;Treilleux, I;Guastalla, Jean Paul;Van Vreckem, Ann;Sylvester, R.;Piccart-Gebhart, Martine
Référence Clinical breast cancer, 1, 3, page (233-40; discussion 241-2)
Publication Publié, 2000-10

Article révisé par les pairs

• Détails
• Contenu

Titre:	A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923.
Auteur:	Hamilton, Andrew; Larsimont, Denis; Paridaens, R.; Drijkoningen, M; Van de Vijver, Marc J; Bruning, Peter; Hanby, A; Houston, S; Treilleux, I; Guastalla, Jean Paul; Van Vreckem, Ann; Sylvester, R.; Piccart-Gebhart, Martine
Informations sur la publication:	Clinical breast cancer, 1, 3, page (233-40; discussion 241-2)
Statut de publication:	Publié, 2000-10
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Adult
	Aged
	Antibiotics, Antineoplastic -- therapeutic use
	Antineoplastic Agents, Phytogenic -- therapeutic use
	Breast Neoplasms -- drug therapy
	Breast Neoplasms -- metabolism
	Breast Neoplasms -- pathology
	Doxorubicin -- therapeutic use
	Female
	Forecasting
	Humans
	Immunoenzyme Techniques
	Middle Aged
	Paclitaxel -- therapeutic use
	Prognosis
	Prospective Studies
	Proto-Oncogene Proteins c-bcl-2 -- metabolism
	Receptor, erbB-2 -- metabolism
	Tumor Suppressor Protein p53 -- metabolism
Note générale:	Clinical Trial
	Clinical Trial, Phase III
	Comparative Study
	Journal Article
	Randomized Controlled Trial
	Research Support, Non-U.S. Gov't
Langue:	Anglais
Identificateurs:	urn:issn:1526-8209
	info:pmid/11899648